The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck

Clinical and Experimental Metastasis

Volumn 19, Issue 4, 2002, Pages 275-282

  Werner, Jochen A ^a   Rathcke, I O ^a   Mandic, R ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Head and neck; Metastasis; MMP; MT MMP; Squamous cell carcinoma; TIMP; Upper aerodigestive tract

Indexed keywords

COLLAGENASE; COLLAGENASE 3; GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

BASEMENT MEMBRANE; CANCER INVASION; EXTRACELLULAR MATRIX; HEAD AND NECK CARCINOMA; HUMAN; METASTASIS; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA;

ANIMALS; BASEMENT MEMBRANE; CARCINOMA, SQUAMOUS CELL; CELL MEMBRANE; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 0036277668     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015531319087     Document Type: Review

References (142)

1. Aktueller stand der versorgung des lymphabflusses maligner kopf-hals-tumoren
2. The organization of ground substance and basement membrane and its significance in tissue injury, disease and growth
3. Identification, distribution, and significance of a collagenolytic enzyme in human tissues
4. Role and regulation of expression of 92-kDa type-IV collagenase (MMP-9) in 2 invasive squamous-cell-carcinoma cell lines of the oral cavity
5. Collagenolytic activity of sarcoma tissues in culture
6. Membrane-type matrix metalloproteinases
7. Changing views of the role of matrix metalloproteinases in metastasis
8. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma
9. Plasminogen activator and cancer
10. Proteolysis in colorectal cancer
11. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas
12. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis
13. Cloning of MMP-26. A novel matrilysin-like proteinase
14. Matrix metalloproteinases: A review
15. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis
16. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis
17. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity
18. Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis
19. Matrix metalloproteinases and their inhibitors in tumour growth and invasion
20. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: Different profiles in trauma and rheumatoid arthritis
21. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain
22. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis
23. Osteoarthritic lesions: Involvement of three different collagenases
24. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis
25. Matrix metalloproteinases and metastasis
26. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family
27. A matrix metalloproteinase expressed on the surface of invasive tumour cells
28. Structure of recombinant mouse collagenase-3 (MMP-13)
29. MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors
30. Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2
31. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
32. Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinases-2
33. Structural biochemistry and activation of matrix metalloproteases
34. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction
35. Biochemical characterization of human collagenase-3
36. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors
37. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme
38. Tissue inhibitors of metalloproteinases: Evolution, structure and function
39. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
40. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours
41. Tumor markers in the diagnosis and follow-up of head and neck cancer: Role of CEA, CA 19-9, SCC, TK, and dTTPase
42. Regulation of matrix metalloproteinases following cellular transformation
43. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules
44. Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma
45. Tumor invasion and extracellular matrix degradative enzymes: Regulation of activity by organ factors
46. Expression of MMP-1, TIMP-1, and type I collagen in laryngeal carcinoma
47. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties
48. Candidate genes for the hypoxic tumor phenotype
49. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells
50. Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands
51. Granulocyte-macrophage colony-stimulating factor upregulates matrix metalloproteinase-2 (MMP-2) and membrane type-1 MMP (MT1-MMP) in human head and neck cancer cells
52. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism
53. Matrix metalloproteinase inhibitors in the treatment of cancer
54. Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-I (MT1-MMP) in human cancer cells
55. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum
56. Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family
57. Involvement of proteasomes in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma
58. Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor
59. Cytokine regulation of gelatinase production by head and neck squamous cell carcinoma: The role of tumor necrosis factor-alpha
60. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion
61. The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells
62. Production of matrix metalloproteinase 9 (92-kDa gelatinase) by human oesophageal squamous cell carcinoma in response to epidermal growth factor
63. Role of membrane type 1-matrix metalloproteinase and gelatinase A in head and neck squamous cell carcinoma invasion in vitro
64. Matrilysin expression and function in airway epithelium
65. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer
66. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization
67. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas
68. Interstitial collagenase gene expression in oral squamous cell carcinoma
69. Induction of M(r) 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts
70. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas
71. Activation of matrix metalloproteinase-2 in head and neck squamous cell carcinoma: Studies of clinical samples and in vitro cell lines co-cultured with fibroblasts
72. Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis
73. Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes
74. Expression of E1AF, an ets-family transcription factor, is correlated with the invasive phenotype of oral squamous cell carcinoma
75. Correlated expression of matrix metalloproteinases and ets family transcription factor E1A-F in invasive oral squamous-cell-carcinoma-derived cell lines
76. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer
77. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis
78. Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx
79. Biochemical interactions of tumor cells with the basement membrane
80. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis
81. General mechanisms of metastasis
82. Expression of MMPS, MT-MMP and TIMPs in squamous cell carcinoma of the oral cavity: Correlations with tumor invasion and metastasis
83. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus
84. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes
85. Matrix metalloproteinase matrilysin (MMP-7) participates in the progression of human gastric and esophageal cancers
86. Contribution of matrilysin (MMP-7) to the metastatic pathway of human cotorectal cancers
87. Matrix metalloproteinases
88. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer
89. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma
90. The relation of gelatinase (MMP-2 and -9) expression with distant site metastasis and tumour aggressiveness in colorectal cancer
91. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy
92. Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer - TIMP-1 as a prognostic marker
93. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy
94. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis
95. Unique activation of matrix metalloproteinase-9 within human liver metastasis from colorectal cancer
96. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients
97. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer
98. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas
99. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma
100. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer
101. Increased incidence of matrix metalloproteinases in urine of cancer patients
102. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension
103. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study
104. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma
105. Production of matrix metalloproteinase 2 (gelatinase/type IV collagenase) and 3 (stromelysin) by cultured oral squamous cell carcinoma
106. Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas
107. Detection of mRNAs encoding collagenase I and stromelysin 2 in carcinomas of the head and neck by in situ hybridization
108. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in laryngeal and pharyngeal squamous cell carcinoma: A quantitative analysis
109. Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis
110. Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines
111. Active-MMP2 in cancer cell nests of oral cancer patients: Correlation with lymph node metastasis
112. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization
113. Activation of matrix metalloproteinase-2 in head and neck squamous cell carcinoma: Studies of clinical samples and in vitro cell lines co-cultured with fibroblasts
114. Expression of matrix metalloproteinase-3 in stage I and II squamous cell carcinoma of the oral cavity
115. Matrix metalloproteinases expressed in squamous cell carcinoma of the oral cavity: Correlation with clinicopathologic features and neo-adjuvant chemotherapy response
116. Angiogenic factors in laryngeal carcinomas: Do they have prognostic relevance?
117. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas
118. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its colocalization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression
119. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme
120. Expression of MMP-2, -7, -9, and -13 as well as TIMP-1, -2, and -3 in squamous cell carcinomas of the head and neck
121. Metalloproteinases and their inhibitors in squamous cell carcinoma of the hypopharynx: Indicators of individual tumor aggressiveness
122. Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer
123. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma
124. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck
125. Expression of invasion markers CD44v6/v3, NM23 and MMP2 in laryngeal and hypopharyngeal carcinoma
126. MMP-13 in oropharyngeal squamous cell carcinoma
127. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma
128. The significance of epidermal growth factor receptor and matrix metalloproteinase-3 in squamous cell carcinoma of the oral cavity
129. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma
130. Mode of tumor invasion in oral squamous cell carcinoma: Improved grading based on immunohistochemical examination of extracellular matrices
131. Prognostische bedeutung von bFGF, VEGF und MMP-2 im serum von patienten mit fortgeschrittenen kopf-hals-tumoren
132. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma
133. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications
134. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
135. An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies
136. Matrix metalloproteinase inhibitors
137. Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines
138. Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole
139. Value of sentinel lymphonodectomy in patients with squamous cell carcinoma of the head and neck
140. Number and location of radiolabeled, intraoperatively identified sentinel nodes in 48 head and neck cancer patients with clinically staged N0 and N1 neck
141. Lymph node topography of the head and neck in New Zealand white rabbits
142. How matrix metalloproteinases regulate cell behavior